Biomanufacturing White Papers and Case Studies

1. Beyond Particle Counting: Why Modern Biologics Need Particle Forensics 4/8/2026

   High particle counts don’t always mean high risk. Identifying particle type and origin—not just quantity—avoids false alarms, protects timelines, and turns data into action.

2. Optimize Time, Space and Cost With Inline Buffer Formulation And System 4/7/2026

   Discover how integrating inline buffer formulation with chromatography reduces buffer waste by 50% and delivers a 710% ROI, transforming downstream efficiency and sustainability.

3. Flexibility In Drug Development: From Tactical Response To Strategic Imperative 4/6/2026

   Build flexibility into your drug development strategy to navigate change effectively, maintain momentum, and drive successful outcomes across every stage of the lifecycle.

4. Early-Phase Injectable Formulation Development 4/6/2026

   Discover how expert-driven strategies and data-centric tools can help you overcome formulation challenges and accelerate the development of stable, high-performance injectable therapeutics.

5. The Effect Of Conventional Cooling Versus Controlled Ice Nucleation On Primary Drying Time 4/1/2026

   See how controlled ice nucleation shortens lyophilization cycles, supports higher drying temperatures, and reduces complexity for amorphous and mixed formulations without sacrificing quality.

6. Biopharma Supply, Reimagined: Regional, Resilient Manufacturing 4/1/2026

   Persistent disruption is redefining biopharma supply chains. Explore how regional manufacturing, integrated risk management, and closer collaboration help build resilience and improve agility.

7. WuXiHigh 2.0 Delivers A 180 mg/mL Formula 3/26/2026

   This case study shows how smart formulation and integrated development achieved a stable 180 mg/mL biologic for subcutaneous delivery, for teams tackling concentration issues.

8. Tailoring Viral Clearance Study Design 3/4/2026

   Viral‑clearance studies need phase‑appropriate design, strong virus stocks, modality‑specific risk assessment, and alignment with evolving regulations for reliable safety outcomes.

9. Complementary Methodologies For Analysis Of NISTmAb Impurities 2/27/2026

   Gain insight into how SEC and CE‑SDS complement each other to assess monoclonal antibody size variants, offering stronger insight into aggregates, fragments, and overall purity.

10. A Journey To Produce MSC-Derived Cell Therapies From Isolation To Large-Scale 2/26/2026

    Drive successful MSC therapy development by optimizing isolation methods, surface chemistry, and closed-system expansion technologies to ensure cellular stability and commercial scalability.